Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 17, 2018

Study Completion Date

December 17, 2018

Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DRUG

eteplirsen

Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.

Trial Locations (13)

19104

Children's Hospital of Philadelphia, Philadelphia

30318

Rare Disease Research Center, Atlanta

30324

Children's Hospital of Atlanta, Atlanta

32610

University of Florida, Shands Hospital, Gainesville

43205

Nationwide Children's Hospital, Columbus

52242

University of Iowa Children's Hospital, Iowa City

63110

St. Louis Children's Hospital, St Louis

85028

Neuromuscular Research Center of Arizona, Phoenix

90095

Ronald Reagan UCLA Medical Center, Los Angeles

94305

Stanford University Medical Center, Stanford

95817

University of California, Davis Medical Center, Sacramento

97239

Shriners Hospital for Children, Portland

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT02420379 - Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter